The artificial intelligence (AI)-powered technology reportedly offers decreased noise magnitude while enhancing image reconstruction for cardiovascular computed tomography (CT) scanners.
The Food and Drug Adminstration (FDA) has granted 510(k) clearance for the addition of deep learning image reconstruction (DLIR) to the Spotlight™ cardiovascular computed tomography (CT) and Spotlight Duo cardiothoracic CT systems.
Utilizing an advanced convolutional neural network (CNN), the DLIR technology maintains high-contrast spatial resolution while reducing pixel-wise noise magnitude, according to Arineta Cardio Imaging, the manufacturer of the aforementioned CT systems.
Trained on more than three billion image data points, the DLIR technology enhances the use of cross-sectional images for cardiovascular imaging assessment in a variety of settings.
“We have used Arineta cardiac CT systems for several years, and they provide the highest quality cardiac CT clinical images for our practice. From our FDA 510(k) reader study, Arineta’s DLIR technology continues that excellence. Arineta’s SpotLight systems make the highest performance cardiac CT available at point-of-care, in an office, mobile, or cath lab setting,” said Matthew Budoff, M.D., the director of Cardiac Computed Tomography within the Division of Cardiology at the Harbor-UCLA Medical Center in Torrance, Ca.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.